CDK9-IN-10
CAS No. 3542-63-0
CDK9-IN-10( —— )
Catalog No. M26101 CAS No. 3542-63-0
CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 68 | Get Quote |
|
| 10MG | 120 | Get Quote |
|
| 25MG | 255 | Get Quote |
|
| 50MG | 410 | Get Quote |
|
| 100MG | 605 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCDK9-IN-10
-
NoteResearch use only, not for human use.
-
Brief DescriptionCDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.
-
DescriptionCDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorE3 Ligase Ligand-Linker Conjugate
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number3542-63-0
-
Formula Weight360.365
-
Molecular FormulaC22H16O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 100 mg/mL (277.50 mM)
-
SMILESOc1cc(OCc2ccccc2)c(O)c2oc(cc(=O)c12)-c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Chan KH, et al. Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. J Med Chem. 2018 Jan 25;61(2):504-513.
molnova catalog
related products
-
Eciruciclib
Eciruciclib is an inhibitor of CDK with antitumor properties.
-
Mevociclib
Mevociclib is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.
-
Furanodiene
Furanodiene has anti-inflammatory and antioxidant activities, it is active against gram-positive bacteria and Candida albicans.The in vitro effects of Furanodiene were examined on two human breast cancer cell lines, MCF-7 and MDA-MB-231 cells.
Cart
sales@molnova.com